Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.50 |
| ▸ | GSK3B | P49841 | 4/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | PPIA | P62937 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1360356 | 0.84 | GSK3B (0.46) | PTPN1GSK3BHPGDSPOLBMAPT | |
| SCHEMBL26657030 | 0.82 | HPGDS (0.43) | PTPN1GSK3BHPGDSMAPTLMNA | |
| SCHEMBL29777919 | 0.81 | TSHR (0.52) | PPIAPOLBMAPTLMNAGAA | |
| SCHEMBL27576279 | 0.81 | MAPT (0.42) | PPIAPOLBMAPTLMNAGAA | |
| SCHEMBL8239082 | 0.81 | TSHR (0.52) | PPIAPOLBMAPTLMNAGAA | |
| SCHEMBL9409754 | 0.79 | PTPN1 (0.65) | PTPN1GSK3BHPGDSMAPTMEN1 | |
| SCHEMBL28662371 | 0.78 | TSHR (0.39) | PPIAPOLBMAPTLMNAGAA | |
| SCHEMBL2558412 | 0.78 | PPIA (0.38) | PPIAPOLBMAPTLMNAHTT | |
| SCHEMBL31575826 | 0.78 | PPIA (0.43) | PPIAPOLBMAPTLMNAMEN1 | |
| SCHEMBL31000747 | 0.77 | PPIA (0.45) | PPIAPOLBMAPTLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219486-A1 | NOVEL BRIDGED BICYCLOALKYL-SUBSTITUTED AMINOTHIZOLES AND THEIR METHODS OF USE | Temple University of the Commonwealth System of Higher Education (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4219486-A1 | NOVEL BRIDGED BICYCLOALKYL-SUBSTITUTED AMINOTHIZOLES AND THEIR METHODS OF USE | Temple University of the Commonwealth System of Higher Education (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3571196-B1 | NOVEL BRIDGED BICYCLOALKYL-SUBSTITUTED AMINOTHIZOLES AND THEIR METHODS OF USE | UNIV TEMPLE (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-3571196-B1 | NOVEL BRIDGED BICYCLOALKYL-SUBSTITUTED AMINOTHIZOLES AND THEIR METHODS OF USE | UNIV TEMPLE (US) | 2023-01-04 | — | — | EP | disclosed |
| US-10941126-B2 | Bridged bicycloalkyl-substituted aminothiazoles and their methods of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-03-09 | — | — | US | disclosed |
| US-10941126-B2 | Bridged bicycloalkyl-substituted aminothiazoles and their methods of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-03-09 | — | — | US | disclosed |
| US-20190352272-A1 | Novel Bridged Bicycloalkyl-Substituted Aminothiazoles and Their Methods of Use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2019-11-21 | — | — | US | disclosed |
| US-20190352272-A1 | Novel Bridged Bicycloalkyl-Substituted Aminothiazoles and Their Methods of Use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2019-11-21 | — | — | US | disclosed |
| US-10112936-B2 | Five-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-10-30 | — | — | US | disclosed |
| WO-2018136766-A1 | NOVEL BRIDGED BICYCLOALKYL-SUBSTITUTED AMINOTHIZOLES AND THEIR METHODS OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-07-26 | — | — | WO | disclosed |
| US-20080146632-A1 | Fc Receptor Modulating Compounds and Compositions | TRILLIUM THERAPEUTICS, INC. (CA) | 2008-06-19 | — | — | US | disclosed |
| US-7332631-B2 | These compounds typically have a core lipophilic group, substituted with a group rich in pi -electrons, preferably having a delocalised pi -electron system; typically include at least one acidic group having a pi -electron system; Autoimmune diseases | TRILLIUM THERAPEUTICS INC. (CA) | 2008-02-19 | — | — | US | disclosed |
| CN-101006063-A | Five-membered heterocycles useful as serine protease inhibitors. | BRISTOL MYERS SQUIBB CO (US) | 2007-07-25 | — | — | CN | disclosed |
| EP-1773786-A2 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060264484-A1 | Fc receptor modulating compounds and compositions | THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD (AU) | 2006-11-23 | — | — | US | disclosed |
| WO-2005123050-A2 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050282805-A1 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-22 | — | — | US | disclosed |
| EP-1585745-A1 | FC RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | Arthron Limited (AU) | 2005-10-19 | — | — | EP | disclosed |
| US-20050009894-A1 | Benzimidazole derivatives and their use as KDR kinase protein inhibitors | AVENTIS PHARMA S.A. (FR) | 2005-01-13 | — | — | US | disclosed |
| WO-2004058747-A1 | FC RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | ARTHRON LIMITED (AU) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10112936-B2 | Five-membered heterocycles useful as serine protease inhibitors | F12, F11, F5 | PTPN1 1612/4885GSK3B 846/4885HPGDS 910/4885 |
| US-20080146632-A1 | Fc Receptor Modulating Compounds and Compositions | FCGR1A, FCGR2A, FCGR3B | PTPN1 470/4885GSK3B 4284/4885HPGDS 832/4885 |
| US-20060264484-A1 | Fc receptor modulating compounds and compositions | FCGR1A, FCGR2A, FCGR3B | PTPN1 448/4885GSK3B 4455/4885HPGDS 824/4885 |
| US-20050009894-A1 | Benzimidazole derivatives and their use as KDR kinase protein inhibitors | KDR, MUSK, FLT4 | PTPN1 1784/4885GSK3B 430/4885HPGDS 2192/4885 |
| US-10941126-B2 | Bridged bicycloalkyl-substituted aminothiazoles and their methods of use | BRCA1, AADAC, BCAT1 | PTPN1 3661/4885GSK3B 3445/4885HPGDS 1036/4885 |
| US-20190352272-A1 | Novel Bridged Bicycloalkyl-Substituted Aminothiazoles and Their Methods of Use | BRCA1, AADAC, BRDT | PTPN1 3825/4885GSK3B 3742/4885HPGDS 1182/4885 |
| US-20050282805-A1 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | F11, TFPI, F12 | PTPN1 2563/4885GSK3B 1316/4885HPGDS 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.